and Teva have announced and even made some early investments.  Bio-Similars appear to have the makings of the next “generic” type of drug, not completely generic, but a drug with the same outcome at a cheaper price.  In other news today the company announced the elimination of 900 positions, mostly sales. 
yet.  BD 
WASHINGTON -(Dow Jones)- A Johnson & Johnson (JNJ) policy director on Tuesday said the health-care conglomerate (more…)